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Abstract
Background In cultured NIH3T3 cells, P311 binds
to the transforming growth factor-beta (TGF-b)-1
latency-associated protein (LAP) and induces the
myofibroblast phenotype. In this study, we deter-
mined the levels of P311 and TGF-b1 proteins in
tubulointerstitial tissue of patients with different
severities of immunoglobulin-A nephropathy (IgAN),
and analyzed the relationships between P311 protein
expression and clinical data.
Methods A total of 57 patients with IgAN and 5
controls (from partial nephrectomy) were included.
P311 and TGF-b1 protein expression were measured
by immunohistochemistry and clinical data (protein-
uria, serum creatinine (Scr), eGFR and biopsy index)
were recorded. The relationship between P311, TGF-
b1, and clinical data was analyzed.
Results P311 expression was significantly higher in
the kidneys of IgAN patients than in controls and was
higher in patients with advanced pathological grades
of IgAN. P311 protein expression in tubulointerstitial
tissue correlated with TGF-b1 and proteinuria. P311
expression was higher in patients with Scr [
133 lmol/L than in patients with Scr \ 133 lmol/L.
Conclusion P311 protein expression in the kidneys
of IgAN patients correlates with TGF-b1 expression
and with proteinuria. P311 might be a key cytokine in
renal fibrosis and be involved in the progression of
IgAN.
Keywords Clinical data  Immunoglobulin A
nephropathy  P311  Tubulointerstitial fibrosis 
TGF-b latency-associated protein
Introduction
Tubulointerstitial fibrosis, the loss of renal tubules
and accumulation of extracellular matrix (ECM)
proteins leads to end stage renal failure [1, 2].
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Although tubular epithelial cells can synthesize
numerous ECM proteins [3, 4], myofibroblasts are
apparently the main sources of increased ECM
deposition in renal fibrosis [4–6]. Previous studies
have demonstrated that interstitial myofibroblasts
derive from the differentiation of fibroblasts, migra-
tion of perivascular smooth muscle cells, or local
proliferation [7–10]. Tubular epithelial cells can also
transdifferentiate into myofibroblasts under patholog-
ical conditions, such as those present during tubulo-
interstitial fibrosis. TGF-b1 is a key cytokine that
regulates the progression of tubulointerstitial fibrosis
[11].
The P311 protein, also known as the binding
protein of TGF-b LAP, is an 8-kD protein originally
found in neurons and muscle. A recent study showed
that expression of P311 in NIH3T3 cells induced a
myofibroblast phenotype with low TGF-b1 expres-
sion [12]. Some researchers have suggested that P311
is involved in TGF-b1-independent myofibroblast
transformation and in the progression of fibrosis [13].
However, it is unknown whether P311 has a role in
the progression of renal tubulointerstitial fibrosis,
especially in IgA nepropathy (IgAN).
IgAN is the most common form of primary
glomerulonephritis. Renal tubulointerstitial fibrosis
is an important process in the progression of IgAN
[14]. The pathogenesis of IgAN involves activation
of mesangial cells and secretion of cytokines, such as
TGF-b1 and IL-1, which enhance cell proliferation,
trans-differentiation, and accumulation of ECM,
eventually leading to tubulointerstitial fibrosis [15].
However, no studies have examined the expression of
P311 in tubulointerstitial tissue and the relationship
of P311, TGF-b1, and the clinical features of IgAN
patients. In this study, we measured the expression of
P311 and TGF-b1 in biopsy samples of IgAN
patients, and analyzed the relationship between these
proteins and clinical data.
Methods
Patients and design
Fifty-seven IgAN patients were included in the
present study. The diagnosis of primary IgAN was
based on renal biopsy findings including a predom-
inance of IgA deposits in the glomerular mesangial
areas as detected by immunofluorescence. Patients
with systemic disease such as Scho¨nlein Henoch
purpura, systemic lupus erythematosus, rheumatoid
arthritis, diabetes mellitus, and liver cirrhosis were
excluded. Five adult kidney tissues from partial
nephrectomy for incidentaloma were included as
controls.
The severity of pathological changes was graded
according to Lee’s classification [16, 17]. Grades I
and II were considered as mild; grades III as
moderate; grades IV and V as severe. The severity
of tubulointerstitial lesions was graded according to
the Katafuchi classification [18]. Cumulative score
ranging from 1 to 3 was considered as mild (group I),
cumulative score ranging from 4 to 6 as moderate
(group II), and cumulative score ranging from 7 to 9
as severe (group III).
The severity of proteinuria was classified accord-
ing to 24-h urine protein excretion: \1 g as mild; 1–
3 g as moderate; [3 g as severe. A patient with
systolic blood pressure [130 mmHg or diastolic
blood pressure[80 mmHg was considered hyperten-
sive. Serum creatinine (Scr) level of 133 lmol/L was
considered the upper normal limit. The equation
developed by the MDRD Study Group was used to
calculate eGFR [19]. Then, patients were divided into
different subgroups (Scr [ 133 lmol/L group vs.
Scr \ 133 lmol/L; eGFR \ 59 mL/min/1.73 m2 vs.
eGFR C 60 mL/min/1.73 m2). The Sichuan Univer-
sity Ethics Committee approved this study, and all
participants gave informed consent.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-
embedded tissue sections using polyclonal antibodies
against P311 and TGF-b1. Formalin-fixed, paraffin-
embedded tissue samples were examined. Sections
(3 lm thick) were mounted on polylysine-coated
slides and deparaffinized. Antigen retrieval was
performed by microwave heating for 4 9 5 min
cycles in a citrate buffer (0.01 mol/L, pH 6.0). After
washing with PBS, endogeneous peroxidase activity
was blocked by incubating with 0.03% H2O2 for
10 min, and sections were washed with PBS again.
Then sections were treated with 10% normal goat
serum for 2 h and incubated overnight at 4C with
anti-P311 polyclonal antibody (Biosynthesis Biotech-
nology, BIOS, China) or anti-TGF-b1 polyclonal
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antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). After washing with PBS, sections were
incubated with HRP-labeled goat anti-rabbit P311 or
TGF-b1 antibodies (Biosynthesis Biotechnology,
BIOS, China) for 1 h. After washing again with
PBS, sections were exposed to DAB for 15 min,
counterstained with Mayer’s hematoxylin, and then
mounted. We used single (no primary antibody) and
double (no primary and no secondary antibody)
negative controls. Red-brown granular cytoplasmic
staining was considered as positive.
Statistical analysis
Image-Pro Plus 6.0 was used to analyze the immu-
nostaining results. All data are presented as
means ± SDs. Statistical comparisons (correlation
analysis, ANOVA, and Student’s t-test) were per-
formed with SPSS 13.0 software. The r value
represents the correlation coefficient based on Pear-




Kidney specimens from 57 IgAN patients and five
incidentaloma patients (controls) were analyzed.
According to Lee’s pathological grading, specimens
were classified as control, mild, moderate, or severe.
Table 1 shows the clinical data of patients in these
groups. ANOVA analysis indicated significant dif-
ferences in proteinuria, eGFR, and Scr among these
four groups (P \ 0.05).
Based on Katafuchi pathological cumulative
scores, kidney specimens were classified as control,
group-I, group-II, or group-III. Table 2 shows the
clinical data of patients in these groups. ANOVA
analysis indicated significant differences in eGFR,
Scr, and proteinuria among these four groups
(P \ 0.05).
Expression of P311
Immunohistochemical results indicated that P311 was
not present in the renal interstitium of normal renal
tissues (Fig. 1a). In other words, P311 is not normally
expressed by the tubular epithelial cells and endo-
thelial cells that line the glomerular and peritubular
capillaries. In contrast, there was significant staining
for P311 in the tubular epithelial cells of IgAN
patients (Fig. 2a, b, c). There was a significant
difference in the expression of P311 in normal and
IgAN patients (P \ 0.01). Interestingly, P311 was
not detected in the renal glomerulus of IgAN patients
or controls (Fig. 2d).
ANOVA analysis was performed for the four
groups classified by Lee’s pathological grading
Table 1 Relevant clinical data of subgroups according to Lee’s pathological grading
Object Control Lee’s pathological grading
Mild Moderate Severe
Number 5 27 20 10
Age (years) 33.00 ± 6.29 31.22 ± 10.76 39.40 ± 13.96 35.30 ± 10.22
Males/females 1/4 10/17 11/9 6/4
Blood pressure systolic (mmHg) 114.40 ± 8.68 110.09 ± 35.19 126.19 ± 22.44 134.15 ± 23.66
Blood pressure diastolic (mmHg) 87.80 ± 6.06 71.99 ± 25.62 83.06 ± 17.91 87.60 ± 18.58
Proteinuria quantification (g per 24 h) 0.20 ± 0.08 2.72 ± 2.33 2.41 ± 1.61a 4.69 ± 2.35a,b
Severe proteinuria rate (%) 0 3.33 30.00 70.00
Serum creatinine (lmol/L) 56.12 ± 11.47 92.63 ± 49.42 107.05 ± 28.51a 201.37 ± 244.05a,b
Renal dysfuntion rate (%) 0 3.70 15.00 40.00
GFR (ml/min) – 81.84 ± 32.46 62.69 ± 16.40a 48.39 ± 19.35a,b
Expressed as mean ± SD
a Compared with mild group, P \ 0.05
b Compared with moderate group, P \ 0.05
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(Table 3) and the four groups classified by Katafuchi
pathological cumulative scores (Table 4). The results
showed that the expression of P311 increased as the
extent of tubulointerstitial fibrosis increased.
Expression of TGF-b1
There was weak staining of TGF-b1 in the interstit-
ium of normal renal tissues (Fig. 1b) but significantly
greater staining of TGF-b1 in the interstitium of
IgAN patients (Fig. 3a, b, c). TGF-b1 was also
present in the glomeruli of IgAN patients (Fig. 3d).
As mentioned earlier, ANOVA analysis was
performed for the four groups classified by Lee’s
pathological grading (Table 3) and the four groups
classified by Katafuchi pathological cumulative
scores (Table 4). The results showed that expression
of TGF-b1 increased as the extent of tubulointerstitial
fibrosis increased.
Relationship between P311 and TGF-b1
expression
We also analyzed the relationship between the
expression of P311 and TGF-b1. Our results indicate
that the expression of P311 correlated with the
expression of TGF-b1 (r = 0.921, P \ 0.001) and
that they had similar intracellular locations.
Table 2 Relevant clinical data of subgroups according to Katafuchi pathological cumulative scores
Object Control Katafuchi pathological cumulative scores
I II III
Number 5 33 19 5
Age (years) 33.00 ± 6.29 31.55 ± 10.92 40.21 ± 13.14 35.80 ± 12.13
Males/females 1/4 13/20 10/9 4/1
Blood pressure systolic (mmHg) 114.40 ± 8.68 110.84 ± 32.98 130.04 ± 21.48 141.85 ± 22.61
Blood pressure diastolic (mmHg) 86.80 ± 6.06 73.52 ± 26.29 85.74 ± 12.64 85.15 ± 20.25
Proteinuria quantification (g per 24 h) 0.20 ± 0.08 2.47 ± 1.82 3.24 ± 2.15a 5.06 ± 3.78a,b
Severe proteinuria rate (%) 0 30.30 42.11 80.00
Serum creatinine (lmol/L) 56.12 ± 11.47 89.41 ± 42.72 113.98 ± 28.14a 307.92 ± 325.57a,b
Renal dysfuntion rate (%) 0 3.03 21.05 80.00
GFR (ml/min) – 81.96 ± 28.63 53.95 ± 13.92a 43.52 ± 25.24a,b
Expressed as mean ± SD
a Compared with mild group, P \ 0.05
b Compared with moderate group, P \ 0.05
Fig. 1 Immunostaining of P311 (a) and TGF-b1 (b) in normal renal tissues. Magnification: 9200. Results are from representative
sections of controls
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P311 expression and proteinuria
A total of 24 of 57 IgAN patients had severe
proteinuria ([3 g per 24 h), 24 had moderate pro-
teinuria (1–3 g per 24 h), and 9 had mild proteinuria
(\1 g per 24 h). ANOVA showed that P311 expres-
sion was higher as the severity of proteinuria
increased (Table 5). In addition, there was a signif-
icant correlation between the amount of 24-h urine
protein and P311 expression (r = 0.291, P \ 0.05).
P311 expression and serum creatinine
A total of 19 of 57 IgAN patients had renal
dysfunction (Scr [ 133 lmol/L) before biopsy. The
renal P311 expression in these patients was signifi-
cantly higher than in the remaining 38 IgAN patients
(14.59 ± 15.01% vs. 4.63 ± 8.63%, P \ 0.05).
However, P311 expression was not significantly
correlated with the level of serum creatinine
(r = 0.232, P [ 0.05).
Fig. 2 Immunostaining of P311 in the renal tissues of patients
with different grades of IgA nephropathy. Tubulointerstitial
tissue of a patient from the (a) severe fibrosis group, (b)
moderate fibrosis group, (c) mild fibrosis group, and the (d)
renal glomerulus of a patient from IgAN. The staining of P311
in tubular epithelial cells increases with the degree of
tubulointerstitial fibrosis (a–c), but there is no P311 staining
in renal glomerulus from IgAN (d). Magnification: 9200.
Results are from representative sections of different groups
Table 3 Expression of P311 and TGF-b1 of subgroups according to Lee’s pathological grading
Object Control n = 5 Lee’s pathological grading
Mild, n = 27 Moderate, n = 20 Severe, n = 10
Score of staining intensity for P311 0 1.95 ± 2.75 5.00 ± 7.86c 20.09 ± 15.78a,b
Score of staining intensity for TGF-b1 1.08 ± 1.14 2.42 ± 3.21 5.73 ± 9.22c 26.49 ± 25.41a,b
Expressed as mean ± SD
a Compared with mild group, P \ 0.05
b Compared with moderate group, P \ 0.05
c Compared with mild group, P [ 0.05
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P311 expression and eGFR
In the present study, 6 IgAN patients had eGFRs
greater than 90 mL/min/1.73 m2, 34 patients had
eGFRs of 60–89 mL/min/1.73 m2, 15 patients had
eGFRs of 30–59 mL/min/1.73 m2, and 2 patients had
eGFRs less than 29 mL/min/1.73 m2. We found that
the mean level of P311 protein was higher in patients
with eGFR \ 59 mL/min/1.73 m2 than in those with
eGFR C 60 mL/min/1.73 m2, but this difference was
not significant (4.43 ± 9.18% vs. 8.83 ± 11.69%,
P [ 0.05). P311 expression was not correlated with
eGFR (r = 0.181, P [ 0.05).
P311 expression and other clinical data
A total of 14 IgAN patients had hypertension before
biopsy. A comparison of P311 expression in patients
Table 4 Expression of P311 and TGF-b1 of subgroups according to Katafuchi pathological cumulative scores
Object Control n = 5 Katafuchi pathological cumulative scores
I, n = 33 II, n = 19 III, n = 5
Score of staining intensity for P311 0 2.53 ± 3.72 7.58 ± 12.48c 25.23 ± 11.40a,b
Score of staining intensity for TGF-b1 1.08 ± 1.14 4.23 ± 9.52 9.78 ± 18.22c 23.87 ± 18.67a,b
Expressed as mean ± SD
a Compared with group I, P \ 0.05
b Compared with group II, P \ 0.05
c Compared with group I, P [ 0.05
Fig. 3 Immunostaining of TGF-b1 in the renal tissues of
patients with IgA nephropathy. Tubulointerstitial tissue of a
patient from the (a) severe fibrosis group, (b) moderate fibrosis
group, (c) mild fibrosis group, and the (d) renal glomerulus of a
patient from IgAN. As with P311 (Fig. 2), staining of TGF-b1
in tubular epithelial cells increases with the degree of
tubulointerstitial fibrosis (a–c). There is weak TGF-b1 staining
in the renal glomerulus from IgAN (d). Magnification: 9200.
Results are from representative sections of different groups
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with or without hypertension indicated a significant
difference (12.74 ± 14.82% vs. 4.09 ± 8.82%,
P \ 0.05). However, there was no significant corre-
lation between P311 expression and blood pressure
(r = 0.201, P [ 0.05). In addition, there was no
significant correlation between P311 expression and
patients age (r = 0.137, P [ 0.05).
Discussion
IgAN is the most common form of primary glomer-
ulonephritis. The pathogenesis of IgAN involves
activation of mesangial cells and secretion of cyto-
kines such as TGF-b1 and IL-1 [20, 21]. Tubular
epithelial cells can transdifferentiate into myofibro-
blasts following stimulation by these cytokines,
resulting in increased ECM deposition in tubuloin-
terstitial tissue. The secretion of these cytokines,
tubular epithelial myofibroblast trans-differentiation,
and the accumulation of ECM eventually lead to
tubulointerstitial fibrosis. In IgAN, tubulointerstitial
fibrosis is considered to be the final pathway that
leads to end stage renal failure [1]. Progressive renal
insufficiency develops in about 40% of IgAN patients
25 or more years after initial diagnosis [15].
Numerous cytokines are involved in the progres-
sion of tubulointerstitial fibrosis [22], and TGF-b1 is
one of the most important cytokines controlling this
process. There is a close relationship between the
level of TGF-b1 and the progression of tubulointer-
stitial fibrosis [11, 23]. TGF-b1 promotes tubular
epithelial myofibroblast trans-differentiation [11] and
increases the synthesis and accumulation of ECM
proteins [6].
TGF-b1 is a multi-functional cytokine that is
secreted within tissues as a biologically inactive
complex with LAP. It becomes functionally active
after extracellular modification. After post-transla-
tional processing, TGF-b1 binds non-covalently to
LAP to confer latency. The non-covalent interactions
between TGF-b1 and LAP can be disrupted in vitro
by heat, extremes of pH, and other chaotropic factors.
However, in vivo, the disruption of the LAP and
TGF-b1 complex appears central to activation. Fol-
lowing the cleavage of LAP, the inactive latent
complex of TGF-b1 is converted into a mature
functional protein. Several studies indicate that LAP
may also be important in certain pathological
processes. Zhang et al. showed that LAP can inhibit
some TGF-b1 signals that have a role in fibrosis [24].
A recent study found that LAP has chemotactic and
anti-inflammatory activities that are independent of
the presence of active TGF-b1 [25].
P311 is an intracytoplasmic protein originally
found in neurons and muscle that can bind to TGF-
b LAP [12]. P311 does not belong to any established
protein family, and its biological function remains
largely unknown. In cultured NIH3T3 cells, P311
binds to LAP and induces a myofibroblast phenotype,
upregulates a-SMA, induces FGF-2, VEGF, and
PDGF receptor, upregulates integrins a3 and a5,
and increases cell proliferation [12]. The in vitro
P311-mediated changes differ from the well-charac-
terized myofibroblast trans-differentiation, in that
P311 inhibits the expression of TGF-b1 and TGF-
b2 [13]. These results suggested P311 is involved in
the progression of fibrosis, but it is unknown whether
P311 is also involved in the progression of renal
tubulointerstitial fibrosis, especially in the kidneys of
IgAN patients.
Heretofore, no studies have examined whether
P311 is expressed in the tubulointerstitial tissue of
IgAN patients, and there are no reports on the
relationship between P311, TGF-b1, and clinical data
of patients with IgAN.
Table 5 Expression of P311 in different subgroups according to proteinuria severity
Object Control n = 5 Proteinuria severity
Mild, n = 33 Moderate, n = 19 Severe, n = 5
Score of staining intensity for P311 0 2.73 ± 3.36 9.19 ± 8.37c 18.83 ± 10.07a,b
Expressed as mean ± SD
a Compared with mild group, P \ 0.05
b Compared with moderate group, P \ 0.05
c Compared with mild group, P [ 0.05
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Our study shows that expression of P311 in the
kidneys of IgAN patients was significantly higher
than in normal controls. In addition, greater expres-
sion of P311 was present in the kidneys of patients
with more advanced tubulointerstitial fibrosis. The
mechanism of P311 upregulation in the tubulointer-
stitial tissues of IgAN patients remains unknown. In
the early stages of IgAN, a patient is in a proinflam-
matory state, so this is one possible reason for P311
upregulation.
The expression of TGF-b1 was also elevated in the
kidneys of IgAN patients. Interestingly, the expres-
sion of P311 correlated with the expression of TGF-
b1, and both occurred at similar locations within
cells. It has been demonstrated previously that TGF-
b1 is a key mediator in renal fibrotic progression [11,
23]. In the present study, our results suggest that P311
and TGF-b1 may bind to one another and thereby
induce tubulointerstitial fibrosis in patients with
IgAN.
In the early stages of IgAN, the patient is in a
proinflammatory state, resulting in cell proliferation
and secretion of cytokines such as TGF-b, IL-1, and
CTGF. At the same time, the proinflammatory state
induces upregulation of P311. Considering that P311
binds to TGF-b1 LAP, it may contribute to the
progression of tubulointerstitial fibrosis by several
mechanisms. One possibility is that P311 binds to
TGF-b1 LAP, changes the conformation of LAP, and
depresses LAP function. LAP bound to P311 could
not inhibit TGF-b1 signals that result in fibrosis, and
could not block inflammation. Thus, LAP bound to
P311 would facilitate inflammation and fibrosis.
Another possibility is that elevation of P311 contrib-
utes to activation of latent TGF-b1. Integrins are
crucial for the activation of latent TGF-b1 [26] and
elevated P311 induces upregulation of a-SMA,
induction of integrins, and increased cell proliferation
[12], which promotes the activation of latent TGF-b1.
The active form of TGF-b1 promotes tubular epithe-
lial myofibroblast trans-differentiation, enhances the
synthesis of ECM proteins, and leads to tubulointer-
stitial fibrosis.
A second important finding in this study is that
there was a correlation of P311 expression with
various clinical parameters. Among our IgAN
patients, there was a significant correlation between
24-h proteinuria and expression of P311, and between
P311 expression and extent of tubulointerstitial
fibrosis. This suggests that P311 might be involved
in the progression of IgAN. Although the expression
of P311 in patients with Scr [ 133 lmol/L was
significantly higher than in patients with Scr \
133 lmol/L and normal controls, P311 expression
was not correlated with eGFR or Scr. This study also
showed that expression of P311 and TGF-b1 in
tubulointerstitial tissue from IgAN patients was
higher than that of control patients, and that expres-
sion of these two proteins correlated with various
clinical parameters and kidney lesion classification.
Finally, there is no indication that our findings
would be specific for patients with IgAN. In fact,
P311 expression may also be induced in the kidneys
of patients with other renal diseases or renal damage,
such as acute tubular necrosis or lupus nephritis.
Studies are currently in progress to measure the
expression of P311 in patients with other kidney
impairments and to identify the role of P311 in the
pathogenesis of IgAN.
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